Recovery from remifentanil after plasmapheresis in a paediatric patient with myasthenia gravis
Hasan Hepağuşlar MD,
Sermin Özteki̇n MD,
Emine Çapar MD,
Zahide Elar MD,
Hasan Hepağuşlar MD
Department of Anaesthesiology Dokuz Eylül University Hospital İzmir, Turkey
Search for more papers by this authorSermin Özteki̇n MD
Department of Anaesthesiology Dokuz Eylül University Hospital İzmir, Turkey
Search for more papers by this authorEmine Çapar MD
Department of Anaesthesiology Dokuz Eylül University Hospital İzmir, Turkey
Search for more papers by this authorZahide Elar MD
Department of Anaesthesiology Dokuz Eylül University Hospital İzmir, Turkey
Search for more papers by this authorHasan Hepağuşlar MD,
Sermin Özteki̇n MD,
Emine Çapar MD,
Zahide Elar MD,
Hasan Hepağuşlar MD
Department of Anaesthesiology Dokuz Eylül University Hospital İzmir, Turkey
Search for more papers by this authorSermin Özteki̇n MD
Department of Anaesthesiology Dokuz Eylül University Hospital İzmir, Turkey
Search for more papers by this authorEmine Çapar MD
Department of Anaesthesiology Dokuz Eylül University Hospital İzmir, Turkey
Search for more papers by this authorZahide Elar MD
Department of Anaesthesiology Dokuz Eylül University Hospital İzmir, Turkey
Search for more papers by this author
References
- 1 Davis L, Britten JJ, Morgan A. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia 1997; 52: 244–260.
- 2 Egan TD, Lemmens HJ, Fiset P et al. The pharmacokinetics of the new short-acting opioid remifentanil (G187084B) in healthy adult male volunteers. Anesthesiology 1993; 79: 881–892.
- 3 Clark WF, Rock GA, Buskard N et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131: 453–462.
- 4 Kuks JBM, Skallebaek D. Plasmapheresis in myasthenia gravis. A survey. Transfus Sci 1998; 19: 129–136.
- 5 Evans RT, MacDonald R, Robinson A. Suxamethonium apnoea associated with plasmapheresis. Anaesthesia 1980; 35: 198–201.
- 6 Naik B, Hirshhorn S, Dharnidharka VR. Prolonged neuromuscular block due to cholinesterase depletion by plasmapheresis. J Clin Anesth 2002; 14: 381–384.
- 7 Rosow CE. An overview of remifentanil. Anesth Analg 1999; 89: S1–S3.
- 8 Manullang J, Egan TD. Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency. Anesth Analg 1999; 89: 529–530.
- 9 Davis PJ, Stiller RL, Wilson AS et al. In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase. Anesth Analg 2002; 95: 1305–1307.
- 10 Culley DJ, Crosby G. Neurologic disease. In: B Sweitzer, ed. Handbook of Preoperative Assessment and Management. Philadelphia: Lippincott Williams & Wilkins, 2000: 255–284.
- 11 Lorimer M, Hall R. Remifentanil and propofol total intravenous anaesthesia for thymectomy in myasthenia gravis. Anaesth Intens Care 1998; 26: 210–212.
- 12 Granell Gil M, Garcia Aguado R, Ferrandiz Roca L et al. The Fastrach laryngeal mask, sevoflurane and remifentanil: an an esthetic alternative for the myasthenic patient. Rev Esp Anestesiol Reanim 2001; 48: 85–88.
- 13 Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122–2128.
- 14 Wood GJ, Hall GM. Plasmapheresis and plasma cholinesterase. Br J Anaesth 1978; 50: 945–949.
- 15 Jackson SH, Bailey GWH, Stevens G. Reduced plasma cholinesterase following haemodilutional cardiopulmonary bypass. Anaesthesia 1982; 37: 319–320.
Citing Literature
